TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19952860

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine coadministered with MMR vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMR vaccine alone
Number of subjects: 0
Study: 18850388

Group type: EXPERIMENTAL
Intervention: Mediated intervention (short film)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 15763054

Group type: EXPERIMENTAL
Intervention: Somatostatin administered intravenously at a dosage of 250 mug/h for consecutive 72 hours
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group treated with non-surgical integrated traditional Chinese and Western medicine
Number of subjects: 39
Study: 12428174

Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation (25 mg/day) for 45 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10894073

Group type: EXPERIMENTAL
Intervention: Independent-learning materials for teaching chest radiology (12 cases)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no independent-learning materials)
Number of subjects: 58
Study: 7781401

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with etoposide/cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy/chest irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery as sole treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 0
Study: 2340741

Group type: EXPERIMENTAL
Intervention: 1.0 U heparin/mL
Number of subjects: 104

Group type: COMPARATOR
Intervention: 0.25 U heparin/mL
Number of subjects: 104
Study: 6459045

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30843921

Group type: EXPERIMENTAL
Intervention: MMR-Bio vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 0
Study: 28028150

Group type: EXPERIMENTAL
Intervention: SST+tPA
Number of subjects: 0
Study: 25747582

Group type: EXPERIMENTAL
Intervention: CTG STV
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: DV p95
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: DV no A
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Late ductus changes (DV no A)
Number of subjects: 503
Study: 24437236

Group type: EXPERIMENTAL
Intervention: Cefixime (suprax solutab) 400 mg 1 time a day for 7 days
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (amoksiklav) 625 mg 3 times a day for 7 days
Number of subjects: 112

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 112
Study: 22225439

Group type: EXPERIMENTAL
Intervention: Expert concept map advance organizer
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control lecture
Number of subjects: 46
Study: 19363013

Group type: EXPERIMENTAL
Intervention: Restorative care (Res-Care) intervention
Number of subjects: 556

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 556
Study: 17513537

Group type: EXPERIMENTAL
Intervention: Topical morphine sulphate
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intrasite gel and water (placebo)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Jelonet dressing (control)
Number of subjects: 49
Study: 15309452

Group type: EXPERIMENTAL
Intervention: NUTRIOSE FB (low-digestible carbohydrate) at a level of 100 g DM/d
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 10
Study: 12058086

Group type: EXPERIMENTAL
Intervention: Motor wrist-to-palm conduction velocity (W-P MCV)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sensory wrist-to-palm conduction velocity (W-P SCV)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 2L-INT (median-second lumbrical and ulnar-interossei muscles)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: M-U (median-thenar and ulnar-hypothenar muscles)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Median motor distal latency (MDL)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sensory distal latency
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combination of W-P MCV and W-P SCV
Number of subjects: 116
Study: 10418043

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) secondary prophylaxis, mean posology 2,400 mg (1,600‐4,000) per day, during mean 10 months (median 4 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 39
Study: 7574048

Group type: EXPERIMENTAL
Intervention: PCHE equivalent to activity present in 2.5, 5, 7.5, 15, or 25 ml/kg of human plasma
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PCHE equivalent to activity present in 25 ml/kg of human plasma
Number of subjects: 48

Group type: COMPARATOR
Intervention: Spontaneous recovery group (8 subjects)
Number of subjects: 48
Study: 2040990

Group type: EXPERIMENTAL
Intervention: Tympanic thermometer measurements
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pulmonary artery catheter measurements
Number of subjects: 20
Study: 6455096

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31863599

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 30379832

Group type: EXPERIMENTAL
Intervention: BioNumerics software for MIRU-VNTR typing
Number of subjects: 272

Group type: COMPARATOR
Intervention: GeneMapper software for MIRU-VNTR typing
Number of subjects: 272
Study: 27779456

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (other antihypertensive treatments)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (Lercanidipine and Control)
Number of subjects: 61
Study: 24742399

Group type: EXPERIMENTAL
Intervention: Positive marital assessments by men
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Positive appraisals
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Negative marital profile
Number of subjects: 1110
Study: 22251379

Group type: EXPERIMENTAL
Intervention: Inductive reasoning training supplemented by weekly crossword and Sudoku puzzles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 20207663

Group type: EXPERIMENTAL
Intervention: Loss framed screening invitations
Number of subjects: 116

Group type: COMPARATOR
Intervention: Gain framed screening invitations
Number of subjects: 116
Study: 16904652

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16298062

Group type: EXPERIMENTAL
Intervention: PCS-S (Pain Catastrophizing Scale - Significant Other)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PCS-S
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher levels of catastrophizing in both spouses
Number of subjects: 111
Study: 14650462

Group type: EXPERIMENTAL
Intervention: Cochrane reviews in pain and palliative care
Number of subjects: 100
Study: 9842763

Group type: EXPERIMENTAL
Intervention: Experimenter-generated imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subject-generated imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method of Loci
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagery mnemonics
Number of subjects: 0
Study: 7986467

Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Number of subjects: 30
Study: 2574191

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30320888

Group type: EXPERIMENTAL
Intervention: Y-shaped fasciotome
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metzenbaum scissors
Number of subjects: 20
Study: 29200446

Group type: EXPERIMENTAL
Intervention: profession‐specific educational intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study: 26296647

Group type: EXPERIMENTAL
Intervention: Land or water-based exercise
Number of subjects: 50
Study: 24175685

Group type: EXPERIMENTAL
Intervention: Self-explanation prompts
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Additional practice
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 69
Study: 21593648

Group type: EXPERIMENTAL
Intervention: Study formula alone
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Study formula with BL999
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Microbiota profile in study formulae and breast-fed infants
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Growth measurements, digestive tolerance, and adverse events
Number of subjects: 190
Study: 18433403

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel (GT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Paclitaxel (T)
Number of subjects: 336
Study: 17087671

Group type: EXPERIMENTAL
Intervention: Sexual health education programmes
Number of subjects: 14
Study: 12856494

Group type: EXPERIMENTAL
Intervention: Cervical vagus nerve stimulation (VNS); duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment; duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervical vagus nerve stimulation (VNS); longer-term follow-up (1 year and 2 years).
Number of subjects: 0
Study: 10862808

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg q.d., n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg q.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9195495

Group type: EXPERIMENTAL
Intervention: RT plus DBD (200 mg/m2 orally on Days 1-10 every five weeks)
Number of subjects: 238

Group type: COMPARATOR
Intervention: RT plus BCNU (200 mg/m2 intravenously every seven weeks)
Number of subjects: 238
Study: 8435205

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for 18 months
Number of subjects: 359

Group type: COMPARATOR
Intervention: Cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for 6 months
Number of subjects: 359
Study: 2892863

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 30067600

Group type: EXPERIMENTAL
Intervention: Tenofovir exposure
Number of subjects: 27

Group type: COMPARATOR
Intervention: Unexposed to Tenofovir
Number of subjects: 27
Study: 26073422

Group type: EXPERIMENTAL
Intervention: Surgical periodontal treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-surgical periodontal treatment
Number of subjects: 76
Study: 25906560

Group type: EXPERIMENTAL
Intervention: Regular acupuncture combined with acupuncture at trigone of urinary bladder
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular acupuncture (control group)
Number of subjects: 60
Study: 23151532

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 13709

Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 13709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13709
Study: 21597268

Group type: COMPARATOR
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Ureteroscopic Holmium Laser Lithotripsy (URL)
Number of subjects: 526
Study: 19422355

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg i.v. bolus)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Nonsurgical control group
Number of subjects: 78
Study: 16399963

Group type: EXPERIMENTAL
Intervention: Adherent to medication
Number of subjects: 184

Group type: COMPARATOR
Intervention: Nonadherent to medication
Number of subjects: 184
Study: 15308995

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 15603
Study: 10654983

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP) 168 microg twice daily (n = 51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9075038

Group type: EXPERIMENTAL
Intervention: Midazolam plus propofol
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo plus propofol
Number of subjects: 203
Study: 8342393

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 0.018 IU/kg/day for 1 month followed by 0.036 IU/kg/day for 1 month
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2872717

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of synthetic somatostatin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of secretin (280 pmol/kg‐h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of cholecystokinin (pharmacological dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of gastric inhibitory polypeptide (GIP) (physiological range)
Number of subjects: 6
Study: 31197249

Group type: EXPERIMENTAL
Intervention: Antibiotic group (omeprazole, amoxicillin, and clarithromycin; n=201)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (omeprazole plus placebo; n=203)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Overweight patients (n=213)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Normal body weight patients (n=167)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Patients with increased baseline waist circumference (n=156)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Patients without increased baseline waist circumference (n=224)
Number of subjects: 404
Study: 30124726

Group type: EXPERIMENTAL
Intervention: 30 mg Toreforant
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 60 mg Toreforant
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26795846

Group type: EXPERIMENTAL
Intervention: Escitalopram (24-week double-blind placebo-controlled trial)
Number of subjects: 969

Group type: COMPARATOR
Intervention: Usual care (placebo or medical treatment only)
Number of subjects: 969
Study: 24933136

Group type: EXPERIMENTAL
Intervention: Online intervention with health behavior monitoring, targeted messaging, and incentives for healthy goods and services
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 122

Group type: COMPARATOR
Intervention: American Cancer Society's Guide to Quitting Smoking online
Number of subjects: 122
Study: 21919551

Group type: EXPERIMENTAL
Intervention: Two-stage single-volume exchange transfusion (TSSV-ET)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Traditional single-stage double-volume exchange transfusion (SSDV-ET)
Number of subjects: 104
Study: 20890191

Group type: EXPERIMENTAL
Intervention: Adiponectin measured within 48 hrs of respiratory failure (Apn1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Adiponectin increase at day 6 (Apn6)
Number of subjects: 175
Study: 18343244

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg QD
Number of subjects: 249

Group type: COMPARATOR
Intervention: Diclofenac 50 mg TID
Number of subjects: 249
Study: 16194413

Group type: EXPERIMENTAL
Intervention: Benazepril (10-20 mg/d) in group A (Scr 133-265 micromol/L)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Benazepril (10-20 mg/d) in group B1 (Scr 266-442 micromol/L)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Calcium-channel antagonist and/or beta-blocker and/or vasodilator in group B2 (control group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Benazepril in group A
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Benazepril in group B1
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Benazepril in group A, group B1, and control group B2
Number of subjects: 168
Study: 12598257

Group type: EXPERIMENTAL
Intervention: Large-dose gentamicin (4 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Modest-dose gentamicin (1.2 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No gentamicin (NG)
Number of subjects: 70
Study: 10374804

Group type: EXPERIMENTAL
Intervention: Self-care education (self-care manual and two 2-hour seminars)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no self-care education)
Number of subjects: 120
Study: 8730613

Group type: COMPARATOR
Intervention: Energy intake estimated by weighted dietary inventory during days 1‐3 and 16‐18 of convalescence.
Number of subjects: 4

Group type: COMPARATOR
Intervention: Energy intake of 261kJ/kg/24h (95% CL of 440kJ/kg/24h) meets the maintenance energy requirement (MER).
Number of subjects: 4

Group type: COMPARATOR
Intervention: Linear relationship between B (y) and ME (x) given by y = 0.85x - 206.6 when B = 0, ME = MER.
Number of subjects: 4
Study: 8470311

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Proguanil (PROG)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Chloroquine and Proguanil combination (CQ+PROG)
Number of subjects: 327
Study: 2983910

Group type: EXPERIMENTAL
Intervention: Etomidate (0.26 mg/kg i.v.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Thiopentone (5.0 mg/kg i.v.)
Number of subjects: 14
Study: 30245755

Group type: EXPERIMENTAL
Intervention: Kudiezi injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine treatments
Number of subjects: 0
Study: 27831712

Group type: EXPERIMENTAL
Intervention: Thoughts and feelings intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improvement intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study: 24903081

Group type: EXPERIMENTAL
Intervention: Football training (n = 20)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 31
Study: 22264332

Group type: EXPERIMENTAL
Intervention: Bibliotherapy with therapist support (n = 44)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Bibliotherapy without therapist support (n = 45)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Waiting list control (n = 44)
Number of subjects: 133
Study: 20145666

Group type: EXPERIMENTAL
Intervention: Peptide milk (5 mg/day for 12 weeks, then 50 mg/day for 12 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo milk drink
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Peptide milk
Number of subjects: 89
Study: 18176610

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) 100 mg/kg per day as a 6-h i.v. infusion until normalization of bilirubin, ALT and AST values.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC)
Number of subjects: 160
Study: 15774591

Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Film-screen mammography (FSM)
Number of subjects: 200
Study: 12526248

Group type: EXPERIMENTAL
Intervention: 7 days treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 14 days treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 21 days treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 28 days treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 14 days treatment (recommended duration)
Number of subjects: 40
Study: 10486663

Group type: EXPERIMENTAL
Intervention: Physician's BP measurement
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Nurse's BP measurement
Number of subjects: 258

Group type: COMPARATOR
Intervention: Physician's decision not to modify treatment
Number of subjects: 258
Study: 8595173

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with epidoxorubicin (EPI) 75 mg m‐2 on day 1, leucovorin (LV) 200 mg m‐2 on days 1‐3, and 5-fluorouracil (5‐FU) 450 mg m‐2 on days 1‐3, every 21 days for 7 months
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 103
Study: 1910852

Group type: EXPERIMENTAL
Intervention: Digoxin treatment for 8 weeks (group 2)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Discontinued digoxin treatment 5 weeks post-operation (group 3)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Discontinued digoxin treatment 3 weeks post-operation (group 4)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (group 1) - no spontaneous atrial fibrillation
Number of subjects: 58
Study: 6383135

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 to 3 mg/kg total)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bretylium Tosylate (10 to 30 mg/kg total)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 to 3 mg/kg total) in patients on digitalis preparations
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bretylium Tosylate (10 to 30 mg/kg total) in patients on digitalis preparations
Number of subjects: 91
Study: 31489826

Group type: EXPERIMENTAL
Intervention: Video modelling
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 48
Study: 29953482

Group type: EXPERIMENTAL
Intervention: Hypertrophy (HYP) RE with 5 sets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Strength endurance (SE) RE with 5 sets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low intensity (LI) RE with 5 sets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Maximum power (MAX) RE with 5 sets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low intensity (LI) RE with 10 sets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hypertrophy (HYP) RE with 10 sets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Strength endurance (SE) RE with 10 sets
Number of subjects: 24
Study: 27013014

Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell (PBSC) donation
Number of subjects: 526

Group type: COMPARATOR
Intervention: Bone Marrow (BM) donation
Number of subjects: 526